Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
13.41
-0.40 (-2.90%)
May 15, 2026, 4:00 PM EDT - Market closed
Enanta Pharmaceuticals Revenue
Enanta Pharmaceuticals had revenue of $17.16M in the quarter ending March 31, 2026, with 14.96% growth. This brings the company's revenue in the last twelve months to $69.21M, up 7.37% year-over-year. In the fiscal year ending September 30, 2025, Enanta Pharmaceuticals had annual revenue of $65.32M, down -3.42%.
Revenue (ttm)
$69.21M
Revenue Growth
+7.37%
P/S Ratio
5.63
Revenue / Employee
$576,775
Employees
120
Market Cap
389.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 65.32M | -2.31M | -3.42% |
| Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
| Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
| Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
| Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
| Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
| Sep 30, 2019 | 205.20M | -1.43M | -0.69% |
| Sep 30, 2018 | 206.63M | 103.81M | 100.97% |
| Sep 30, 2017 | 102.81M | 14.55M | 16.48% |
| Sep 30, 2016 | 88.27M | -72.61M | -45.13% |
| Sep 30, 2015 | 160.88M | 113.14M | 236.98% |
| Sep 30, 2014 | 47.74M | 15.69M | 48.94% |
| Sep 30, 2013 | 32.05M | -9.65M | -23.15% |
| Sep 30, 2012 | 41.71M | -176.00K | -0.42% |
| Sep 30, 2011 | 41.88M | 19.12M | 83.99% |
| Sep 30, 2010 | 22.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 217.78M |
| ADC Therapeutics | 79.18M |
| Verastem | 49.59M |
| C4 Therapeutics | 34.86M |
| X4 Pharmaceuticals | 9.01M |
| YD Bio | 510.36K |
ENTA News
- 6 days ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Business Wire
- 13 days ago - Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 - Business Wire
- 4 weeks ago - Enanta announces first participant dosed in Phase 1 trial of EDP-978 - TheFly
- 4 weeks ago - Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - Business Wire
- 5 weeks ago - Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - Business Wire
- 7 weeks ago - Enanta initiated with a Buy at Rodman & Renshaw - TheFly
- 2 months ago - Enanta Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026 - Transcripts